Lyell Immunopharma (LYEL) to Release Earnings on Wednesday

Lyell Immunopharma (NASDAQ:LYEL) is expected to be releasing its earnings data on Wednesday, February 26th. Analysts expect Lyell Immunopharma to post earnings of ($0.20) per share for the quarter.

Lyell Immunopharma Trading Down 0.1 %

Shares of NASDAQ:LYEL opened at $0.61 on Wednesday. Lyell Immunopharma has a twelve month low of $0.51 and a twelve month high of $3.26. The company’s 50 day moving average is $0.62 and its 200 day moving average is $1.01. The company has a market cap of $178.04 million, a PE ratio of -0.77 and a beta of -0.35.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Bank of America cut shares of Lyell Immunopharma from a “buy” rating to an “underperform” rating and dropped their price objective for the stock from $6.00 to $1.00 in a research note on Wednesday, October 30th. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price objective on shares of Lyell Immunopharma in a research note on Tuesday, November 12th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.